These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12171565)

  • 1. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
    Li Q; Zhu GD
    Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
    Graves PR; Yu L; Schwarz JK; Gales J; Sausville EA; O'Connor PM; Piwnica-Worms H
    J Biol Chem; 2000 Feb; 275(8):5600-5. PubMed ID: 10681541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Chk1 by activated PKB/Akt.
    King FW; Skeen J; Hay N; Shtivelman E
    Cell Cycle; 2004 May; 3(5):634-7. PubMed ID: 15107605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
    Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
    Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk1 inhibitors for novel cancer treatment.
    Tao ZF; Lin NH
    Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery targeting Chk1 and Chk2 kinases.
    Zhou BB; Sausville EA
    Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting checkpoint kinase 1 in cancer therapeutics.
    Tse AN; Carvajal R; Schwartz GK
    Clin Cancer Res; 2007 Apr; 13(7):1955-60. PubMed ID: 17404075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis.
    Jin ZH; Kurosu T; Yamaguchi M; Arai A; Miura O
    Oncogene; 2005 Mar; 24(12):1973-81. PubMed ID: 15674326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of Cdc2/cyclin B activation in Xenopus egg extracts via inhibitory phosphorylation of Cdc25C phosphatase by Ca(2+)/calmodulin-dependent protein [corrected] kinase II.
    Hutchins JR; Dikovskaya D; Clarke PR
    Mol Biol Cell; 2003 Oct; 14(10):4003-14. PubMed ID: 14517314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
    Shtivelman E
    Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
    Dietlein F; Kalb B; Jokic M; Noll EM; Strong A; Tharun L; Ozretić L; Künstlinger H; Kambartel K; Randerath WJ; Jüngst C; Schmitt A; Torgovnick A; Richters A; Rauh D; Siedek F; Persigehl T; Mauch C; Bartkova J; Bradley A; Sprick MR; Trumpp A; Rad R; Saur D; Bartek J; Wolf J; Büttner R; Thomas RK; Reinhardt HC
    Cell; 2015 Jul; 162(1):146-59. PubMed ID: 26140595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1.
    Hiromura M; Okada F; Obata T; Auguin D; Shibata T; Roumestand C; Noguchi M
    J Biol Chem; 2004 Dec; 279(51):53407-18. PubMed ID: 15459205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
    Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
    PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.
    Jackson JR; Gilmartin A; Imburgia C; Winkler JD; Marshall LA; Roshak A
    Cancer Res; 2000 Feb; 60(3):566-72. PubMed ID: 10676638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
    Zenvirt S; Kravchenko-Balasha N; Levitzki A
    Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle.
    Shtivelman E; Sussman J; Stokoe D
    Curr Biol; 2002 Jun; 12(11):919-24. PubMed ID: 12062056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways.
    Ouyang G; Yao L; Ruan K; Song G; Mao Y; Bao S
    Cell Biol Int; 2009 Dec; 33(12):1237-44. PubMed ID: 19732843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.